Key CPNDS Impacts

  • CPNDS researchers published reports that led to new labelling of prescriptions containing codeine, a common pain reliever that until recently, was considered to be compatible with breastfeeding. Network investigators discovered that in some mothers, codeine can be metabolized into toxic amounts of morphine that are life-threatening for breastfed infants. As a result, Health Canada, the U.S. Food and Drug Administration and industry changed labelling to alert consumers of the potential dangers of codeine.
  • CPNDS has discovered the genetic cause of cisplatin-induced hearing loss in children, which is the first step in the development of predictive diagnostic markers to reduce the incidence of cisplatin ototoxicity, thereby improving treatment outcomes.
  • CPNDS has identified multiple genetic variants associated with anthracycline-induced cardiotoxicity, which when combined with clinical risk factors, may be used to identify high-risk patients who can then be provided with safer treatment options.